E. Bargagli (Firenze (FI), Italy), N. Chaudhuri (Manchester (Greater Manchester), United Kingdom)
Late Breaking Abstract - SMOKING PREVALENCE AND CHARACTERIZATION OF PATIENTS AT DIAGNOSIS OF DIFFUSE INTERSTITIAL LUNG DISEASES
N. Albacar Ingla (Barcelona, Spain), S. Cuerpo (Barcelona, Spain), F. Hernández-González (Barcelona, Spain), E. Barbeta (Barcelona, Spain), C. Lucena (Barcelona, Spain), M. Boada (Barcelona, Spain), G. Espinosa (Barcelona, Spain), R. Castellanos (Barcelona, Spain), O. Viñas (Barcelona, Spain), A. Xaubet (Barcelona, Spain), C. Agustí (Barcelona, Spain), S. Prieto (Barcelona, Spain), J. Ramírez (Barcelona, Spain), M. Sánchez (Barcelona, Spain), J. Sellarés (Barcelona, Spain)
|    |
LSC - 2018 - Physical and biochemical interactions drive fibrocytes accumulation in the scleroderma lung matrix
H. Sun, J. Winkler (julia.winkler@yale.edu / Yale University,New Haven), M. Minasyan (maksym.minasyan@yale.edu / Yale University,New Haven), H. Pan (hongyi.pan@yale.edu / Yale University,New Haven), O. Desai (Omkar.desai@yale.edu / Yale University,New Haven), A. Pellowe (Amanda.pellowe@yale.edu / Yale University,New Haven), J. Li (jia.li.jl2875@yale.edu / Shanghai Jiao Tong University,Shanghai), X. Peng (xueyan.peng@yale.edu / Yale University,New Haven), A. Gonzalez (Anjelica.gonzalez@yale.edu / Yale University,New Haven), E. Herzog (erica.herzog@yale.edu / Yale University,New Haven)
|  |
Confocal Laser Endomicroscopy (CLE) for Differentiating the Underlying Cause of Ground Glass Opacities in ILD Patients
L. Wijmans (Amsterdam, Netherlands), D. De Bruin (Amsterdam, Netherlands), J. Roelofs (Amsterdam, Netherlands), I. Van Den Berk (Amsterdam, Netherlands), R. Jonkers (Amsterdam, Netherlands), P. Bonta (Amsterdam, Netherlands), V. Poletti (Aarhus Denmark and Forli, Italy), J. Annema (Amsterdam, Netherlands)
| |
Nintedanib inhibits contractile activity of lung myofibroblasts in a cellular model of scleroderma associated pulmonary fibrosis
G. Bogatkevich (Charleston, United States of America), I. Atanelishvili (Charleston, United States of America), T. Akter (Charleston, United States of America), L. Wollin (Biberach, Germany), R. Silver (Charleston, United States of America)
| |
Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network
M. Kreuter (Heidelberg, Germany), F. Bonella (Essen, Germany), N. Blank (Heidelberg , Germany), E. Siegert (Berlin, Germany), J. Henes (Tuebingen, Germany), M. Worm (Berlin , Germany), C. Sunderkoetter (Muenster, Germany), M. Schmalzing (Wuerzburg, Germany), A. Kreuter (Oberhausen , Germany), C. Guenther (Bochum , Germany), L. Susok (Bochum , Germany), G. Zeidler (Treuenbrietzen, Germany), I. Koetter (Hamburg, Germany), U. Mueller-Ladner (Bad Nauheim, Germany), T. Krieg (Cologne, Germany), A. Juche (Berlin, Germany), T. Schmeiser (Wuppertal, Germany), G. Riemekasten (Luebeck , Germany), E. Aberer (Graz, Austria), N. Gaebelein-Wissing (Wuppertal, Germany), J. Distler (Erlangen, Germany), M. Sardy (Munich, Germany), C. Pfeiffer (Ulm, Germany), K. Kuhr (Cologne, Germany), H. Lorenz (Heidelberg , Germany), P. Moinzadeh (Cologne, Germany), N. Hunzelmann (Cologne, Germany)
| |
Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease
A. Olson (Denver, United States of America), T. Maher (London, United Kingdom), M. Salisbury (Ann Arbor, United States of America), V. Acciai (Ingelheim am Rhein, Germany), B. Mounir (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Zouad-Lejour (Ingelheim am Rhein, Germany), C. Wells (Burlington, United States of America), A. Fischer (Denver, United States of America)
| |
Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: A population-based study
A. Rittig (Aarhus, Denmark), O. Hilberg (Vejle, Denmark), A. Løkke (Aarhus, Denmark)
| |
The antifibrotic effect of Imatinib loaded CD44 targeted gold nanoparticles (Im-CD44-GNP) relies on alveolar macrophage regulation
F. Meloni (Pavia, Italy), M. Morosini (Pavia, Italy), V. Codullo (Pavia, Italy), V. Frangipane (Pavia, Italy), S. Magni (Pavia, Italy), H. Recalde (Pavia, Italy), S. Inghilleri (Pavia, Italy), G. Comolli (Pavia, Italy), E. Cova (Pavia, Italy), C. Montecucco (Pavia, Italy), M. Colombo (Milan , Italy), D. Prosperi (Milan , Italy)
| |
Functional analysis of ABCA3 in phosphatidylcholine metabolism
Y. Li (Munich, Germany), S. Kinting (Munich, Germany), S. Hoeppner (Munich, Germany), M. Griese (Munich, Germany)
| |
A retrospective clinical review of drug induced interstitial lung disease at a tertiary cancer centre
F. Walker (Manchester, United Kingdom), R. Broadbent (Manchester, United Kingdom), B. Taylor (Manchester, United Kingdom), S. Tenant (Manchester, United Kingdom), K. Linton (Manchester, United Kingdom)
| |
Prognostic factors in Korean patients with chronic hypersensitivity pneumonitis
Y. Kim (Seoul, Republic of Korea), J. Choe (Seoul, Republic of Korea), E. Chae (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
| |
Serum KL-6 as a marker of disease progression in SSc-ILD
C. Stock (London, United Kingdom), R. Hoyles (London, United Kingdom), C. D'Accord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), C. Campochiaro (London, United Kingdom), J. Donovan (London, United Kingdom), L. Mori (London, United Kingdom), T. Maher (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), V. Ong (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom)
| |
Effect of genotype on hypersensitivity pneumonitis despite treatment.
M. Šterclová (Prague, Czech Republic), M. PetrEk (Olomouc, Czech Republic), A. Kishore (Olomouc, Czech Republic), J. Skibova (Prague, Czech Republic), M. Vasakova (Prague, Czech Republic)
| |
Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats
X. Cui (Wuhan, China), Z. Peng (Wuhan, China), Y. Zhou (Wuhan, China), H. Zhang (Wuhan, China), K. Lipson (San Francisco, United States of America), Y. Liu (Wuhan, China)
| |
Impact of a specialist respiratory pharmacist in the management of interstitial lung disease
M. Naqvi (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. West (London, United Kingdom)
| |
A case series study on re-treatment to lung cancer after drug-induced interstitial lung disease
S. Terada (Nara, Japan), T. Hajiro (Nara, Japan), H. Yutani (Nara, Japan), M. Ueyama (Nara, Japan), T. Nakanishi (Nara, Japan), N. Hamao (Nara, Japan), T. Inao (Nara, Japan), Y. Kaji (Nara, Japan), T. Yasuda (Nara, Japan), S. Hashimoto (Nara, Japan), E. Tanaka (Nara, Japan), Y. Taguchi (Nara, Japan)
| |
Impact Prognostic impact of comorbidities in patients with chronic Hypersensitivity Pneumonitis
J. Wälscher (Heidelberg, Germany), B. Gross (Heidelberg, Germany), J. Bruhwyler (Gembloux, Belgium), J. Morisset (Quebec, Canada), C. Heussel (Heidelberg, Germany), F. Lasitschka (Heidelberg, Germany), F. Herth (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Quality of life of the patients followed for diffuse interstitial pneumonitis with fibrosis
e. lamyae (casablanca, Morocco), J. Hasna (casablanca, Morocco), E. Wiam (casablanca, Morocco), A. Hicham (casablanca, Morocco)
| |